Latest News

Latest News

News from the World Hepatitis Alliance

Calling for greater commitment to the fight against hepatitis at the World Health Assembly

28 May 2015 Bridie Taylor

The 68th session of the World Health Assembly (WHA68) took place in Geneva from 18th-26th May. On 25th May, the World Hepatitis Alliance was invited...

Supporting the launch of guidelines and policies to address viral hepatitis

1 Apr 2015 Bridie Taylor

WHO Injection Safety policy Every year 1.7 million people are infected with hepatitis B through unsafe injection and 315,000 with hepatitis C. Yet up...

Working closely with WHO to develop a global strategy

1 Apr 2015 Bridie Taylor

WHO Strategic and Technical Advisory Committee for hepatitis (STAC-HEP) meeting, Geneva, Switzerland, 19 – 20 February As part of an expert advisory...

Highlighting the importance of patient advocacy at international conferences

31 Mar 2015 Bridie Taylor

24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Istanbul, Turkey, 12 – 15 March Patient led advocacy is vital in...

How does the Alliance really represent hepatitis patients?

28 Feb 2015 Bridie Taylor

The World Hepatitis Alliance prides itself as the true voice of hepatitis patients living all over the world. All our work is overseen by an...

What is the future for hepatitis treatments? And how we can fund hepatitis programmes?

28 Feb 2015 Bridie Taylor

Discussions around hepatitis are dominated by the pioneering new treatments rapidly transforming the landscape and the ensuing heated discussions...

WHA in official relations with WHO: What does this mean for you?

28 Feb 2015 Bridie Taylor

Fundamental to our ability to influence global hepatitis policy and bring about real change in the world of hepatitis is our relationship with the...

Need some inspiration for action? : Initiatives from WHA members

28 Feb 2015 Bridie Taylor

Together our voices are stronger and united we can tackle this global killer! The World Hepatitis Alliance is fortunate enough to be made up of...

How will 2015 be a defining year for the Alliance?

28 Feb 2015 Bridie Taylor

Viral hepatitis is a global killer with alarming mortality rates, yet an increased global commitment to tackling the disease and ground-breaking new...

Exploring new treatment developments and innovative ways to finance healthcare

31 Jan 2015 Bridie Taylor

New therapeutic developments are revolutionising the way hepatitis is treated. But with a global lack of funding, how can these pioneering new drugs...

Assisting WHO in the development of a global strategy

31 Jan 2015 Bridie Taylor

World Health Organization Member States have urged WHO to develop a comprehensive global strategy on hepatitis. To assist in the development of this...

World Hepatitis Alliance’s ever-growing membership base

31 Jan 2015 Bridie Taylor

Central to the success of the World Hepatitis Alliance are our member groups around the world. To stimulate political interest in and action on...

Joining expert committees to promote harm reduction

31 Jan 2015 Bridie Taylor

Harm reduction policies are proven to save lives. Globally, as many as 67% of People Who Inject Drugs (PWIDs) have hepatitis C and an additional 8.4...

Promoting screening among high risk communities with new multi-lingual tool

31 Jan 2015 Bridie Taylor

In Europe, migrant populations are disproportionally affected by hepatitis B and C. Crucial to reducing the burden is improving screening among these...

Supporting the development of national action plans in South America

31 Jan 2015 Bridie Taylor

Government commitment to comprehensive national action plans is key to addressing the burden of viral hepatitis. To support the development of...

Pages

News from infohep

Hepatitis C virtually eliminated in people with HIV in the Netherlands

23 Jul 2021 Keith Alcorn
Hepatitis C has been almost eliminated as a health problem for people living with HIV in the Netherlands due to direct-acting antiviral treatment...

Immunotherapy plus arterial infusion chemotherapy shows promise for advanced liver cancer

12 Jul 2021 Liz Highleyman
An experimental immune checkpoint inhibitor plus chemotherapy delivered directly into the hepatic artery in the liver led to good outcomes in people...

COVID-19 vaccine responses are weaker in liver transplant patients

8 Jul 2021 Keith Alcorn
Liver transplant recipients in Israel were less likely to develop antibodies after a second dose of the Pfizer SARS-CoV-2 vaccine than healthy...

Weaker COVID-19 vaccine responses seen in people with advanced liver fibrosis

5 Jul 2021 Liz Highleyman
Among people with non-alcoholic fatty liver disease (NAFLD), those with more advanced liver fibrosis did not respond as well to the Pfizer-BioNTech...

Resmetirom reduces liver fat and fibrosis in people with NASH

1 Jul 2021 Liz Highleyman
Resmetirom, a thyroid hormone receptor agonist, appeared to reduce liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in...

Peer support improved hepatitis C treatment uptake and completion in England

30 Jun 2021 Keith Alcorn
Peer support increased hepatitis C treatment initiation and completion in England between 2017 and 2020, an evaluation of a national peer support...

Reflex testing successfully uncovers hidden hepatitis C cases in Scotland

29 Jun 2021 Keith Alcorn
Automatic viral hepatitis testing of blood samples from patients with abnormal liver function has the potential to identify “hard to reach” people...

Food insecurity raises the risk of death in people with fatty liver disease

28 Jun 2021 Keith Alcorn
Food insecurity – limited or unreliable food supplies due to poverty – was associated with an increased risk of death in US adults with non-alcoholic...

Bulevirtide appears safe and effective for hepatitis D

28 Jun 2021 Liz Highleyman
The entry inhibitor bulevirtide (Hepcludex) suppressed hepatitis delta viral load and improved liver enzyme levels in a phase III clinical trial,...

Advanced cirrhosis or alcohol use disorder raised the risk of COVID-19 death in France

25 Jun 2021 Keith Alcorn
People with advanced cirrhosis or alcohol use disorder were significantly more likely to die from COVID-19 in France during 2020 compared to the rest...